# Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

> **NCT06581562** · PHASE1 · RECRUITING · sponsor: **IRIS Research and Development, LLC** · enrollment: 30 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Pemphigus Vulgaris
- Granulomatosis With Polyangiitis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** AB-101
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06581562
- **Lead sponsor:** IRIS Research and Development, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2027-07
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581562, "Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06581562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*